Seeking Alpha

Meridian Bioscience (VIVO -1.4%) says it's successfully completed beta trials for two new...

Meridian Bioscience (VIVO -1.4%) says it's successfully completed beta trials for two new illumigene molecular amplification tests. The assays are designed to specifically detect the DNA of Chlamydia trachomatis and Neisseria gonorrhoeae from both swab and urine samples.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector